PT  - JOURNAL ARTICLE
AU  - Jingqi Zhou
AU  - Chang Liu
AU  - Michael Francis
AU  - Yitang Sun
AU  - Moon-Suhn Ryu
AU  - Arthur Grider
AU  - Kaixiong Ye
TI  - The Causal Effects of Blood Iron and Copper on Lipid Metabolism Disease: Evidence from Phenome-wide Mendelian Randomization Study
AID  - 10.1101/2020.09.17.20196956
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.09.17.20196956
4099  - http://medrxiv.org/content/early/2020/09/22/2020.09.17.20196956.short
4100  - http://medrxiv.org/content/early/2020/09/22/2020.09.17.20196956.full
AB  - Background Blood levels of iron and copper, even within their normal ranges, have been associated with a wide range of clinical outcomes. Available epidemiological evidence on blood iron and copper association with potential clinical effects, such as lipid metabolism disorder, is inconsistent and scarce. This study aims to examine and disentangle the causal clinical effects of iron and copper.Methods Genetic instruments for the blood level of iron and copper were curated from existing genome-wide association studies. Candidate clinical outcomes were identified based on a phenome-wide association study (PheWAS) between these genetic instruments and multiple phenotypes in 310,999 unrelated individuals of European ancestry from the UK Biobank. All signals passing stringent correction for multiple testing were followed by Mendelian randomization (MR) analyses, with replication in independent data sources where possible.Results Genetically predicted higher blood levels of iron and copper are both associated with lower risks of iron deficiency anemia (OR = 0.75, 95% CI:0.67-0.85, p =1.90×10−06 for iron; OR= 0.88, 95% CI: 0.78-0.98, p =0.03 for cooper), lipid metabolism disorders and its two subcategories, hyperlipidemia (OR = 0.90, 95% CI:0.85-0.96, p =6.44×10−04 for iron; OR = 0.92, 95% CI:0.87-0.98, p = 5.51×10−03 for cooper) and hypercholesterolemia (OR = 0.90, 95% CI:0.84-0.95, p = 5.34×10−04 for iron; OR = 0.93, 95% CI:0.89–0.99, p =0.02 for cooper). Consistently, they are also associated with lower blood levels of total cholesterol and low-density lipoprotein cholesterol. Multiple sensitivity tests were applied to assess the pleiotropy and stability of the estimation, and consistent evidence across different approaches was obtained. Additionally, unique clinical effects of each blood mineral were also pinpointed, and sex-stratified MR analysis further revealed the clinical implication of iron and copper exhibits some degree of sex differences.Conclusions Our comparative PheWAS-MR study of iron and copper comprehensively characterized their shared and unique clinical effects, highlighting their novel causal roles in hyperlipidemia and hypercholesterolemia. Given the modifiable and variable nature of blood mineral status, these findings warrant further investigation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAG is supported by United States Department of Agriculture, National Institute of Food and Agriculture Hatch Funds. MSR is supported by the Allen Foundation Inc., and the United States Department of Agriculture (MIN-18-118). KY is supported by the University of Georgia Research Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UK Biobank project was approved by the North West Multi-Centre Research Ethics Committee.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGenetic and phenotypic data from UK Biobank could be accessed following an application and approval process. Summary statistics generated in this project are provided in the supplementary files.CADcoronary artery diseaseFDRfalse discovery rateGLGCGlobal Lipids Genetics ConsortiumICDInternational Classification of DiseasesIVWinverse variance-weightedGRSpolygenic risk scoreGWASgenome-wide association studyHDLhigh-density lipoprotein cholesterolLDLlow-density lipoprotein cholesterolMRmendelian randomizationORodds ratioOAOsteoarthrosisPheWASphenome-wide association studySNPsingle nucleotide polymorphismSDstandard deviationT2Dtype 2 diabetesTCtotal cholesterolWMweighted median